Following a court order, HHS won't fire more than 2,800 probationary employees it sought to cut — but it won't let them come ...

In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead ...

A teenage boy who received Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys died from liver failure, the biotech ...

Kurt Knight, former Amwell exec, named CEO of nutrition telehealth company Foodsmart. Company raised $200M from TPG, serves 2.2M+ members via Medicaid, Medicare & commercial plans.

Cell therapy biotech RegCell is hoping to bridge science from Japan with the US biotech industry to develop new cell therapies for autoimmune conditions.

Arbor Biotechnologies, a startup founded by CRISPR pioneer Feng Zhang nine years ago, has closed a $73.9 million Series C financing to bring its first therapy into clinical trials ...

Sofinnova Partners launches €165M Biovelocita II fund for early-stage science in Italy, France, UK & Denmark, backed by Amgen ...

The Trump administration defended HHS’ rejection of drugmakers' 340B rebate models “at this time,” but suggested that the ...

AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple ...

A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the ...

At the end of Robert F. Kennedy Jr.'s confirmation hearing, Senate HELP Committee Chairman Bill Cassidy (R-LA) raised a rhetorical question at the heart of whether Kennedy was the moderate he’d ...

Incyte's povorcitinib meets endpoints in hidradenitis suppurativa trials but shows lower efficacy than expected, lagging behind UCB's Bimzelx in Phase 3 studies.